Navigation Links
Bioheart, Inc. Announces Loan to be Assumed by Seaside
Date:10/1/2010

SUNRISE, Fla., Oct. 1 /PRNewswire/ -- Bioheart, Inc. - (OTC Bulletin Board: BHRT) a company focused on the discovery, development and commercialization of autologous cell therapies for the treatment of cardiovascular diseases, announced today that the company received a preliminary commitment from Seaside National Bank and Trust for a $980,000 loan that will be used to refinance the Company's loan with Bank of America. The loan is subject to completion of definitive documentation and the delivery to Seaside of certificates of deposit of third parties. The Company further advised that $367,244 of the Bank of America loan would be paid down by a member of the Company's Board of Directors. In exchange, the Board Member will receive restricted common shares and warrants.

About Bioheart, Inc.Bioheart is committed to maintaining a leading position within the cardiovascular sector of the cell technology industry, delivering cell therapies, intelligent devices and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues.  Bioheart works to prevent the worsening of any condition with devices that monitor and diagnose. The company's goals are to enable damaged tissue to be regenerated, if possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. MyoCell is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.

For more information on Bioheart, visit www.bioheartinc.com.

Forward-Looking Statements:Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.  Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements. These risk factors include, without limitation, (i) our ability to obtain additional financing; (ii) our ability to control and reduce our expenses; (iii) our ability to establish a distribution network for and commence distribution of certain products for which we have acquired distribution rights; (iv) our ability to timely and successfully complete our clinical trials; (v) the occurrence of any unacceptable side effects during or after preclinical and clinical testing of our product candidates; (vi) the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; (vii) our dependence on the success of our lead product candidate; (viii) our inability to predict the extent of our future losses or if or when we will become profitable; (ix) our ability to protect our intellectual property rights; and (x) intense competition. The Company is also subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2009, and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2010.Contact:Catherine Sulawske Guck, Chief Operating Officer954 835 1500bioheart@bioheartinc.com  
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Bioheart, Inc. Announces Additional Funding Support
2. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
3. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
4. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
5. Anesiva Announces Second Quarter 2008 Financial Results and Update
6. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
7. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
8. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. ThirdBiotech Announces Kemeta as Newest Sponsor
11. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... Columbia , Feb. 21, 2017  OncoGenex Pharmaceuticals, Inc. ... from two randomized Phase 2 clinical trials were presented at ... Symposium, held February 16 th - 18 th in ... bladder and prostate cancers demonstrated apatorsen was well-tolerated and improved ... ...
(Date:2/21/2017)... , February 21, 2017 Scientists ... for Adoption by Plastic Industry  ... STEER, creator of ... materials in the fields of plastics, pharmaceuticals, food and nutraceuticals, ... Merck, a leading science & technology company, on creating ...
(Date:2/20/2017)... ... 2017 , ... Global relationship marketing company Nerium International ... membership in the Canadian Direct Sellers Association (DSA) effective immediately. , Nerium ... Olson in 2011. Today Nerium International, with its cutting edge, anti-aging skincare ...
(Date:2/20/2017)... 20, 2017 This report analyzes the worldwide markets ... Types: Xylanase, Amylase, Cellulase, and Others. The report provides separate ... Japan , Europe , ... , and Rest of World. Read the ... forecasts are provided for the period 2015 through 2022. Also, ...
Breaking Biology Technology:
(Date:1/26/2017)...  Crossmatch, a leading provider of security and identity ... combatting fraud, waste and abuse in assistance operations around ... on Disaster Relief conference in Panama City ... and foreign assistance organizations throughout Latin America ... a largely unacknowledged problem in the foreign assistance and ...
(Date:1/24/2017)... 24, 2017 Biopharm Reports has carried ... use of nuclear magnetic resonance spectroscopy (NMR). This ... profiled current practices, developments, trends and end-user plans ... growth and opportunities. These areas include growth in ... needs and innovation requirements, hyphenated NMR techniques, main ...
(Date:1/21/2017)... 2017 Research and Markets has announced the ... report to their offering. ... The global voice recognition biometrics market to grow at ... The report covers the present scenario and the growth prospects of ... market size, the report considers the revenue generated from the sales ...
Breaking Biology News(10 mins):